Evidence map›Paper›PMID 42732180›Full record

ArticleBioinformatics and biology insights2026

Novel Pyrazoline Derivatives as Therapeutic Candidate for Alzheimer's Disease: An Integrated Network Pharmacology and 3D-QSAR Modelling.

Md Mainuddin Hossain, Towfika Rahman Singdha, Saiful Islam Sakib, Juthi Adhikari, Prottay Choudhury, Md Sumon Miya, Ashis K Sarker, Mukta Das, Abu Zaffar Shibly

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioinformatics and biology insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Md Mainuddin HossainDepartment of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh Tangail, Bangladesh.ORCID https://orcid.org/0009-0005-7076-3235
Towfika Rahman SingdhaDepartment of Chemistry, Mawlana Bhashani Science and Technology University, Santosh, Tangail, Bangladesh.
Saiful Islam SakibDepartment of Chemistry, Mawlana Bhashani Science and Technology University, Santosh, Tangail, Bangladesh.
Juthi AdhikariDepartment of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh Tangail, Bangladesh.
Prottay ChoudhuryDepartment of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh Tangail, Bangladesh.
Md Sumon MiyaDepartment of Chemistry, Mawlana Bhashani Science and Technology University, Santosh, Tangail, Bangladesh.
Ashis K SarkerDepartment of Chemistry, Mawlana Bhashani Science and Technology University, Santosh, Tangail, Bangladesh.
Mukta DasDepartment of Chemistry, Mawlana Bhashani Science and Technology University, Santosh, Tangail, Bangladesh.
Abu Zaffar ShiblyDepartment of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh Tangail, Bangladesh.ORCID https://orcid.org/0000-0002-0464-8125

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a complex neurodegenerative condition marked by amyloid-β accumulation, tau pathology, and neuroinflammation, while current single-target therapies largely provide symptomatic relief without effectively halting disease progression. Therefore, the rational design and synthesis of novel small molecules capable of simultaneously modulating multiple AD-related targets represent a promising therapeutic strategy. Based on this rationale, novel pyrazoline derivatives were synthesized and their therapeutic potential was evaluated using an integrative computational framework. AD-related genes were retrieved from GeneCards, CTD, and DisGeNET databases, and hub genes were identified through topological and centrality analyses, followed by functional enrichment analyses to explore their biological relevance. Molecular docking was used to evaluate the binding affinities of the synthesized compounds toward the identified hub targets, while 3D-QSAR modeling was used to predict their inhibitory potential. A total of 63 common genes were identified across the three databases, with APOE, BACE1, and CSF1R emerging as key hub genes. Enrichment analysis revealed their involvement in PI3K-Akt, mTOR, NF-κB, TNF, AMPK, and FoxO signaling pathways associated with amyloid processing, tau pathology, and neuroinflammation. Among the evaluated compounds, compound 2a exhibited the strongest binding affinities toward the hub targets along with favorable drug-likeness, pharmacokinetics, toxicity, and promising IC

Indexed as

Alzheimer’s diseaseamyloid-β accumulationmulti-target therapypyrazoline derivativessynthesized compound

Identifiers

PMID42732180
PMCPMC13570014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.